Into a Deeper Understanding of CYP2D6's Role in Risperidone Monotherapy and the Potential Side Effects in Schizophrenia Spectrum Disorders.

Publisher: MDPI Country of Publication: Switzerland NLM ID: 101092791 Publication Model: Electronic Cited Medium: Internet ISSN: 1422-0067 (Electronic) Linking ISSN: 14220067 NLM ISO Abbreviation: Int J Mol Sci Subsets: MEDLINE

Original Publication: Basel, Switzerland : MDPI, [2000-

Cytochrome P-450 CYP2D6*/genetics ; Cytochrome P-450 CYP2D6*/metabolism ; Risperidone*/adverse effects ; Risperidone*/therapeutic use ; Schizophrenia*/drug therapy ; Antipsychotic Agents*/adverse effects ; Antipsychotic Agents*/therapeutic use; Humans ; Male ; Female ; Adult ; Middle Aged ; Genotype ; Young Adult

Schizophrenia spectrum disorders (SSD) are a group of diseases characterized by one or more abnormal features in perception, thought processing and behavior. Patients suffering from SSD are at risk of developing life-threatening complications. Pharmacogenetic studies have shown promising results on personalized treatment of psychosis. In the current study, 103 patients diagnosed with SSD treated with risperidone as antipsychotic monotherapy were enrolled. Socio-demographics and clinical data were recorded, and laboratory tests and genotyping standard procedure for cytochrome P450 (CYP) 2D6*4 were performed. Patients were evaluated by the Positive and Negative Syndrome Scale (PANSS) on admission and at discharge. Based on the reduction in the PANSS total score, subjects were divided into non-responders, partial responders and full responders. Only 11 subjects had a full response to risperidone (10.67%), 53 subjects (51.45%) had a partial response, and 39 participants (37.86%) were non-responders. Patients at first episode psychosis showed significantly higher levels of blood glucose and prolactin levels, while chronic patients showed significantly higher LDL levels. Adverse drug reactions (ADR) such as tremor and stiffness significantly correlated with genetic phenotypes ( p = 0.0145). While CYP2D6 showed no impact on treatment response, ADR were significantly more frequent among poor and intermediate metabolizers.

BMC Psychiatry. 2020 Apr 5;20(1):149. (PMID: 32248839)
Indian J Psychol Med. 2018 Jul-Aug;40(4):335-342. (PMID: 30093744)
Front Psychiatry. 2019 Aug 30;10:633. (PMID: 31543842)
Lancet Psychiatry. 2019 May;6(5):418-426. (PMID: 31000417)
Eur J Pharm Sci. 2010 Oct 9;41(2):289-98. (PMID: 20599499)
Schizophr Res. 2006 Feb 28;82(2-3):213-23. (PMID: 16229988)
Acta Psychiatr Scand. 2018 Feb;137(2):98-108. (PMID: 29280500)
Curr Drug Metab. 2008 Jun;9(5):410-8. (PMID: 18537577)
Psychiatry Res. 1988 Jan;23(1):99-110. (PMID: 3363019)
Sci Rep. 2021 Feb 18;11(1):4158. (PMID: 33603025)
Biomedicines. 2024 Feb 22;12(3):. (PMID: 38540107)
Schizophr Bull. 2017 Oct 21;43(6):1280-1290. (PMID: 28586480)
Curr Drug Targets. 2004 Aug;5(6):573-9. (PMID: 15270204)
Environ Res. 2023 Sep 1;232:116305. (PMID: 37268204)
Bangladesh Med Res Counc Bull. 2015 Dec;41(3):144-150. (PMID: 29870170)
Am J Psychiatry. 2005 May;162(5):947-53. (PMID: 15863797)
Schizophr Res. 2024 Feb;264:272-279. (PMID: 38198879)
World J Psychiatry. 2012 Oct 22;2(5):74-82. (PMID: 24175171)
J Clin Psychopharmacol. 2016 Apr;36(2):125-9. (PMID: 26848792)
Pharmacogenet Genomics. 2009 Feb;19(2):170-9. (PMID: 19151603)
Int J Neuropsychopharmacol. 2013 Jul;16(6):1205-18. (PMID: 23199972)
Br J Clin Pharmacol. 2004 May;57(5):569-75. (PMID: 15089809)
Neuro Endocrinol Lett. 2012;33(2):236-44. (PMID: 22592207)
Psychoneuroendocrinology. 2023 Dec;158:106392. (PMID: 37778198)
Curr Pharm Biotechnol. 2017;18(3):194-203. (PMID: 28240172)
Basic Clin Pharmacol Toxicol. 2018 Jul;123(1):42-50. (PMID: 29369497)
Neuropsychiatr Dis Treat. 2015 Dec 21;12:15-24. (PMID: 26730193)
Front Pharmacol. 2021 Jul 14;12:711940. (PMID: 34335273)
Syst Rev. 2020 Jan 16;9(1):17. (PMID: 31948489)
Schizophr Res Treatment. 2011;2011:631690. (PMID: 22937271)
Neuropsychiatr Dis Treat. 2011;7:611-20. (PMID: 22090797)
Behav Brain Res. 2021 Mar 5;401:113058. (PMID: 33316324)
J Pharm Health Care Sci. 2018 Nov 19;4:28. (PMID: 30479825)
Int Clin Psychopharmacol. 2005 Mar;20(2):71-8. (PMID: 15729081)
Pharmacotherapy. 2015 Sep;35(9):813-22. (PMID: 26406773)
Schizophr Res. 2015 Feb;161(2-3):429-33. (PMID: 25556080)
Br J Psychiatry. 2004 Jun;184:509-16. (PMID: 15172945)
Psychiatry Res. 2016 Jun 30;240:209-213. (PMID: 27111215)
Eur Arch Psychiatry Clin Neurosci. 2005 Aug;255(4):261-8. (PMID: 15565299)
Appl Transl Genom. 2015 May 14;5:40-6. (PMID: 26937359)
Nat Rev Dis Primers. 2015 Nov 12;1:15067. (PMID: 27189524)
Int J Mol Sci. 2021 Jan 02;22(1):. (PMID: 33401717)
Mol Diagn Ther. 2013 Jun;17(3):165-84. (PMID: 23588782)
Iran J Psychiatry Behav Sci. 2016 Sep 04;10(3):e7988. (PMID: 27822286)
Neurol Clin. 2011 Feb;29(1):127-48, viii. (PMID: 21172575)
Bull Exp Biol Med. 2016 Mar;160(5):687-90. (PMID: 27021090)
Pharmgenomics Pers Med. 2016 Dec 01;9:131-147. (PMID: 27942231)
Int J Clin Pract. 2007 Apr;61(4):653-62. (PMID: 17343660)
Ir J Med Sci. 2019 Nov;188(4):1417-1422. (PMID: 30771137)
J Clin Psychiatry. 2005 Jan;66(1):15-27. (PMID: 15669884)
J Psychiatr Res. 2024 Jun;174:137-152. (PMID: 38631139)
Pharmacogenet Genomics. 2013 Nov;23(11):627-30. (PMID: 24026091)
Ann Hum Genet. 2010 Jul;74(4):340-50. (PMID: 20597905)
Eur J Clin Pharmacol. 2010 Nov;66(11):1109-17. (PMID: 20563569)
Eur J Clin Pharmacol. 2008 May;64(5):465-75. (PMID: 18202841)
Curr Med Res Opin. 2021 Oct;37(10):1811-1819. (PMID: 34281472)
BMC Psychiatry. 2021 Feb 3;21(1):70. (PMID: 33535976)

Keywords: CYP2D6; risperidone treatment; schizophrenia spectrum disorders

EC 1.14.14.1 (Cytochrome P-450 CYP2D6)
L6UH7ZF8HC (Risperidone)
0 (Antipsychotic Agents)

Date Created: 20240627 Date Completed: 20240627 Latest Revision: 20240717

20250114

PMC11204263

10.3390/ijms25126350

38928058